Diffuse Large B-cell Lymphoma
Conditions
Brief summary
A Multicenter, Prospective, Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide (cR2) in Real-world Practice in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Detailed description
This is a prospective, multicenter, observational investigator-initiated clinical study. The subjects were adults (18 years of age and older) diagnosed with relapsed/refractory diffuse large B-cell lymphoma who will begin cR2 therapy at the time of enrollment. Patients were required to complete a visit every 4 weeks, lasting 24 weeks from the first dosing of the study protocol. The first visit was considered an enrollment visit. The specific dosage of cR2 will be determined according to the standard clinical practice of the treating physician. Participation in the study did not affect treatment decisions. Patients who could not continue with the cR2 regimen would terminate the visit early and then withdraw from the study. According to the data collected from the experiment, the safety and effectiveness of the research scheme were analyzed.
Interventions
DRUGChidamide
Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
DRUGLenalidomide
Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
DRUGRituximab
Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
Sponsors
Second Affiliated Hospital of Soochow University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The decision of treating physicians to make cR2 regimen was not related to whether they participated in the study or not; 2. Age 18 and above, no gender limitation; 3. Patients with pathologically confirmed diffuse large B-cell lymphoma (DLBCL) who have relapsed or failed to respond to at least one systemic therapy; 4. Have at least one measurable lesion: any length of lymph node lesion ≥1.5cm or any length of extrinsic lesion \> 1cm; 5. The serum pregnancy test of female subjects of childbearing age was negative; 6. Understand the test procedure and content, and sign the informed consent voluntarily.
Exclusion criteria
1. The decision of treating physicians to make cR2 regimen was not related to whether they participated in the study or not; 2. Age 18 and above, no gender limitation; 3. Patients with pathologically confirmed diffuse large B-cell lymphoma (DLBCL) who have relapsed or failed to respond to at least one systemic therapy; 4. Have at least one measurable lesion: any length of lymph node lesion ≥1.5cm or any length of extrinsic lesion \> 1cm; 5. The serum pregnancy test of female subjects of childbearing age was negative; 6. Understand the test procedure and content, and sign the informed consent voluntarily.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | 30 months | Objective response rates assessed by the investigator |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 30 months | Incidence of adverse events |
Other
| Measure | Time frame | Description |
|---|---|---|
| Complete response rate | 30 months | Complete response rate |
| Progression-free survival | 30 months | Progression-free survival |
| Overall survival time | 30 months | Overall survival time |
Countries
China
Outcome results
None listed